Table 2.
Clinical trials with Ang-2 and VEGF-axis combination therapies (active and/or recruiting).
| Angiopoietin-targeted agent | VEGF-targeted Agent | Tumor Setting | Clinical Trial |
|---|---|---|---|
| Phase I | |||
| MEDI3617 | Bevacizumab | Solid tumors | NCT01248949 |
| Nesvacumab (REGN910) | Ziv-Aflibercept | Solid tumors | NCT01688960 |
| Phase II | |||
| Trebananib | Bevacizumab | mCRC | NCT01249521 |
| Trebananib | Bevacizumab | RCC | NCT01664182 |
| Pazopanib | |||
| Sorafenib | |||
| Sunitinib | |||
| Trebananib | Bevacizumab | Glioblastoma | NCT01609790 |
| Trebananib | Bevacizumab | Metastatic breast cancer | NCT00511459 |
| Trebananib | Sorafenib | HCC | NCT00872014 |
| Trebananib | Sunitinib | RCC | NCT00853372 |
| Trebananib | Sorafenib | RCC | NCT00467025 |
mCRC: metastatic colorectal cancer, RCC: renal cell carcinoma, HCC: hepatocellular carcinoma.